Glaukos (GKOS) Set to Announce Earnings on Wednesday

Glaukos (NYSE:GKOS - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Wednesday, May 1st. Analysts expect Glaukos to post earnings of ($0.59) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.07). The business had revenue of $82.40 million during the quarter, compared to analyst estimates of $81.00 million. Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. Glaukos's revenue was up 15.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.53) earnings per share. On average, analysts expect Glaukos to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Glaukos Price Performance

NYSE GKOS traded down $0.07 during trading hours on Wednesday, reaching $101.03. The company's stock had a trading volume of 521,714 shares, compared to its average volume of 664,936. The stock has a market cap of $5.07 billion, a PE ratio of -36.31 and a beta of 1.08. Glaukos has a fifty-two week low of $45.38 and a fifty-two week high of $103.66. The company's 50-day moving average is $92.08 and its two-hundred day moving average is $81.28. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34.

Insider Buying and Selling

In other Glaukos news, COO Joseph E. Gilliam sold 59,801 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $100.47, for a total value of $6,008,206.47. Following the completion of the sale, the chief operating officer now owns 101,845 shares of the company's stock, valued at $10,232,367.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Glaukos news, CFO Alex R. Thurman sold 1,372 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $100.54, for a total value of $137,940.88. Following the completion of the sale, the chief financial officer now owns 52,532 shares of the company's stock, valued at $5,281,567.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 59,801 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $100.47, for a total transaction of $6,008,206.47. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares of the company's stock, valued at approximately $10,232,367.15. The disclosure for this sale can be found here. In the last quarter, insiders sold 242,357 shares of company stock valued at $22,857,372. 7.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Wells Fargo & Company increased their price objective on shares of Glaukos from $83.00 to $103.00 and gave the company an "overweight" rating in a research note on Thursday, February 22nd. Citigroup increased their price objective on shares of Glaukos from $107.00 to $120.00 and gave the stock a "buy" rating in a report on Monday, March 25th. Stifel Nicolaus reiterated a "buy" rating and set a $110.00 price objective on shares of Glaukos in a report on Wednesday, April 3rd. StockNews.com lowered shares of Glaukos from a "hold" rating to a "sell" rating in a report on Tuesday, February 27th. Finally, Needham & Company LLC increased their price objective on shares of Glaukos from $105.00 to $108.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and an average target price of $99.80.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.